Osteoporosis may be caused due to lower than normal peak bone mass and greater than normal bone loss. It is a chronic and life-threatening disease, in which microstructure of bones is altered due to reduction in bone mass and bone density. The condition leads to increased bone fragility and threat of bone cracks and fractures. Therefore, it is considered life threatening due to severe injury and associated pain. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors and steroids.
The global osteoporosis drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug classes (bisphosphonates, calcitonin, parathyroid hormone therapy drugs, RANK ligand inhibitors, selective estrogen receptor modulators, etc.), clinical pipeline analysis of phase 1, 2 and 3 drugs (Odanacatib, Romosozumab, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global osteoporosis drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global osteoporosis drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global osteoporosis drugs market and included in this report are Actavis plc, Amgen, Inc., Eli Lilly and Company, F. Hoffmann La Roche Ltd., Merck & Co, Inc., Novartis International AG, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.